PT-141 / Bremelanotide

01 · What is it?

The identity comes first.

Bremelanotide is a peptide medicine also known by the development name PT-141. It acts on melanocortin receptors. Its approved use is specific and does not establish universal effects on attraction, relationships or sexual performance.

Scientific classification: Synthetic cyclic peptide; melanocortin receptor agonist

For example. It interacts with selected neural signaling circuits rather than functioning as a general aphrodisiac switch.

02 · How does it work?

The signal, explained.

It activates several melanocortin receptors, including receptors involved in brain signaling and skin pigmentation. The exact sequence connecting those interactions to the approved clinical effect remains incompletely understood.

The key research focus is Melanocortin receptors; MC4R is relevant to proposed central effects. A target describes where an interaction may occur; it does not by itself establish a benefit.

03 · What happens after the signal?

Follow the downstream effects.

Gs/cAMP signaling changes can influence neural activity; MC1R activity relates to pigmentation biology. A receptor profile alone cannot predict an individual’s desire or response.

To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.

04 · What is it commonly researched for?

The questions researchers are asking.

Clinical studies have examined acquired, generalized hypoactive sexual desire disorder in premenopausal women.

These are areas of investigation, not promises about a Maison product.

05 · Body systems involved

Where the biology connects.

Brain

Relevant to neural signaling, appetite, behavior or stress circuitry described above.

Skin

Includes barrier tissue, fibroblasts and hair follicles where applicable; cell findings are not automatically clinical outcomes.

06 · Receptor / target profile

The molecular reference card.

Primary receptor or target

Melanocortin receptors; MC4R is relevant to proposed central effects

Secondary interactions

MC1R and other melanocortin receptor subtypes.

Where it is found

Melanocortin receptors occur in the central nervous system and peripheral tissues including skin.

Activation, inhibition or interaction

Bremelanotide activates several melanocortin receptor subtypes, including MC1R and MC4R. The exact mechanism behind the approved clinical effect is not fully established.

Important downstream pathways

Gs/cAMP signaling changes can influence neural activity; MC1R activity relates to pigmentation biology. A receptor profile alone cannot predict an individual’s desire or response.

07 · Evidence quality

What carries weight—and what does not.

A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.

08 · Who is studying it?

Follow the original research.

No current sponsor-led clinical development program was verified for this exact research identity. This does not prove that no study exists; consult current records and distinguish related molecules.

Regulatory context: Vyleesi has an FDA-approved use. A research PT-141 listing is not the approved formulation.

Registry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.

09 · Research terminology

A small glossary for this page.

Explore the complete foundations glossary

10 · Research status & limitations

Keep the boundaries visible.

Vyleesi has an FDA-approved use. A research PT-141 listing is not the approved formulation.

Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.

The main evidence category here is established or regulatory evidence. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.